| 42.14 0.54 (1.3%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 49.98 |
1-year : | 58.38 |
| Resists | First : | 42.79 |
Second : | 49.98 |
| Pivot price | 42.04  |
|||
| Supports | First : | 41.8 |
Second : | 41.18 |
| MAs | MA(5) : | 41.72 |
MA(20) : | 42.11 |
| MA(100) : | 40.72 |
MA(250) : | 32.45 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 35.9 |
D(3) : | 24.8 |
| RSI | RSI(14): 53.9 |
|||
| 52-week | High : | 43.59 | Low : | 19.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CERE ] has closed below upper band by 41.8%. Bollinger Bands are 75.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 42.28 - 42.48 | 42.48 - 42.67 |
| Low: | 41.19 - 41.43 | 41.43 - 41.65 |
| Close: | 41.75 - 42.14 | 42.14 - 42.49 |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Thu, 18 Apr 2024
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Stud - Benzinga
Thu, 18 Apr 2024
Arizona State Retirement System Increases Stock Holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) - Defense World
Fri, 12 Apr 2024
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Short Interest Up 38.2% in March - MarketBeat
Fri, 12 Apr 2024
Cerevel Therapeutics Sees Unusually High Options Volume (NASDAQ:CERE) - Defense World
Thu, 11 Apr 2024
55,120 Shares in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Acquired by International Assets Investment ... - MarketBeat
Wed, 06 Mar 2024
Cerevel Therapeutics: Parkinson's Could Be The Issue (NASDAQ:CERE) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 182 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 86.5 (%) |
| Shares Short | 9,620 (K) |
| Shares Short P.Month | 7,100 (K) |
| EPS | -2.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.71 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.8 % |
| Return on Equity (ttm) | -72.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -342 (M) |
| Levered Free Cash Flow | -198 (M) |
| PE Ratio | -15.79 |
| PEG Ratio | 0 |
| Price to Book value | 11.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|